Assessment of Sanglifehrin-based Cyclophilin Inhibitors for Hepatocellular Carcinoma Treatment
Among all cancer types, liver cancer has the second highest mortality rate. HCC is the most common liver cancer and patients usually have a very poor prognosis. The standard-of-care drug Sorafenib extends the life expectancy with just two to three months, making the development of new drugs for the treatment of HCC an important area of research. Here, the pharmaceutical candidates SfA1 and SfA2 w
